Eli Lilly Clinical Trial Pipeline — 187 Active Studies

Eli Lilly pipeline at a glance (March 2026)

About the Eli Lilly clinical program

Eli Lilly has transformed its portfolio with two breakthrough platforms: GLP-1/GIP receptor agonists for obesity and diabetes (tirzepatide/Mounjaro, retatrutide, orforglipron) and targeted oncology (Verzenio/abemaciclib in breast cancer, Retevmo/selpercatinib for RET-altered cancers, Jaypirca/pirtobrutinib for B-cell malignancies). The obesity franchise is generating an unprecedented volume of Phase 3 trials across cardiometabolic, liver disease, sleep apnea, kidney disease, and other conditions. In immunology, Omvoh (mirikizumab) for IBD and Olumiant (baricitinib) expansions add breadth beyond oncology and metabolic disease.

Key therapeutic areas

• Obesity / metabolic disease (GLP-1/GIP)
• Oncology (breast, RET-altered, BTK)
• Immunology / IBD
• Diabetes
• Alzheimer's disease (donanemab)

Key pipeline programs

• Mounjaro / Zepbound (tirzepatide) — GLP-1/GIP dual agonist
• Verzenio (abemaciclib) — CDK4/6 inhibitor, breast cancer
• Retevmo (selpercatinib) — RET inhibitor, NSCLC/thyroid/other
• Jaypirca (pirtobrutinib) — non-covalent BTK inhibitor
• Omvoh (mirikizumab) — IL-23p19, IBD
• Donanemab — anti-amyloid beta, Alzheimer's

Top Eli Lilly trial indications

Condition / Indication	Trials
["Healthy"]	13
["Obesity", "Overweight"]	11
["Overweight", "Obesity"]	6
["Alzheimer Disease"]	4
["Obesity"]	4
["Type 2 Diabetes"]	4
["Breast Neoplasms"]	3
["Atopic Dermatitis"]	3

Why monitor Eli Lilly's clinical trial activity

Lilly's tirzepatide/GLP-1 platform is the fastest-growing new drug class in history by trial volume. Any company developing obesity, metabolic, or cardiorenal therapeutics needs real-time visibility into Lilly's expanding label trials. Their oncology pipeline (Verzenio combinations, Retevmo expansions) also generates consistent new Phase 2/3 registrations.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Eli Lilly's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Eli Lilly trials

• Sponsor normalization: Eli Lilly may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

How many obesity / GLP-1 trials does Eli Lilly currently have active?

Eli Lilly's tirzepatide (Mounjaro/Zepbound) is being tested across obesity-related conditions including cardiovascular disease, sleep apnea, fatty liver disease, and kidney disease. DataLookout lets you monitor specifically for new tirzepatide trials in indication categories relevant to your competitive landscape.

How many Eli Lilly trials are currently recruiting?

Based on current ClinicalTrials.gov data, 105 Eli Lilly-sponsored trials are actively recruiting patients across their oncology, metabolic, and immunology programs.

Can DataLookout monitor Lilly's oncology pipeline separately from their metabolic disease trials?

Yes. You can create separate watchlists — one for Lilly oncology programs (filtering by mechanism or indication keywords) and another for their GLP-1 / metabolic pipeline — each delivering a targeted daily digest.